Wegovy for Weight Loss
in India — Semaglutide

Yes. Wegovy (semaglutide 2.4 mg) is DCGI-approved and was launched in India in June 2025 by Novo Nordisk. It is approved specifically for chronic weight management in adults with BMI ≥30 (obesity), or BMI ≥27 with at least one weight-related comorbidity (Type 2 Diabetes, hypertension, dyslipidaemia, fatty liver, sleep apnoea, or CVD). It must be prescribed and supervised by a qualified physician.

After Novo Nordisk's April 2026 price cut of up to 48%, Wegovy now costs ₹5,660/month at starting dose (0.25 mg) and ₹16,400/month at maintenance dose (2.4 mg). For more affordable options of the same molecule, Poviztra (Emcure-Novo second brand) costs ₹3,999–8,999/month, and generic semaglutide starts at ₹1,290/month vial format.

In the STEP-1 clinical trial, patients on 2.4 mg Wegovy lost an average of 14.9% of their body weight over 68 weeks — roughly 15 kg for a 100 kg patient. Individual results vary: predictors of good response include female sex, lower starting HbA1c, absence of long-term insulin use, and consistent adherence to the dosing schedule. Around 32% of trial patients achieved ≥20% weight loss.

For pure weight loss magnitude, Mounjaro produces more (~20% vs ~14% in SURMOUNT-5). But Wegovy has three advantages: (1) it is significantly cheaper, especially with Poviztra and generics available, (2) it has proven cardiovascular outcomes (SELECT trial: 20% MACE reduction) which Mounjaro doesn't yet, and (3) it is FDA-approved for MASH/fatty liver. For most patients, Wegovy is the more sensible long-term choice. See our full Mounjaro vs Wegovy India guide.

Poviztra is Novo Nordisk's second brand of Wegovy in India, distributed by Emcure Pharmaceuticals since December 2025. It is the same 2.4 mg semaglutide injection, manufactured by Novo Nordisk in the same facilities, in the same pre-filled pen device. After the April 2026 price cut, Poviztra costs ₹3,999–8,999/month — roughly 45% cheaper than branded Wegovy. There is no clinical difference between them.

The most common side effects are nausea, diarrhoea, constipation, vomiting, and reduced appetite — particularly during dose escalation. These are usually mild and improve with time. Slower dose titration significantly reduces side effects. Rare but serious risks include pancreatitis, gallbladder disease, and kidney injury from dehydration — which is why medical supervision is essential. See our GLP-1 side effects management guide for detailed help.

Studies show that most patients regain 60–80% of lost weight within 12 months of stopping semaglutide without a structured maintenance plan. Wegovy is best considered an indefinite chronic treatment, similar to how we treat hypertension. If you must stop, Dr. Manuj's programme includes a structured taper and lifestyle anchoring phase to minimise regain.

Wegovy and Ozempic are the same molecule (semaglutide) made by the same manufacturer (Novo Nordisk), but at different doses and approved for different conditions. Wegovy goes up to 2.4 mg and is approved for obesity. Ozempic goes up to 1 mg and is approved for Type 2 Diabetes. For weight loss, the higher Wegovy dose is more effective. In India both are available — see our Ozempic India 2026 price guide for the diabetes indication.

Call or WhatsApp Dr. Manuj Sondhi at +91 88002 62767. Nirvana Clinic, Shop GF-93, Sun Twilight Mall, Opposite Delta 1 Metro Station, Greater Noida. A full consultation with blood tests is required before starting. Same-day appointments often available, Monday–Saturday 9 AM to 8 PM. Online consultations available for patients across India.